SH3 and cysteine rich domain 3Genealiases: CMYO13 · CMYP13 · MYPBB · NAM
Q-omics provides the consensus-scored STAC3 profile across patient tissues and cancer cell-line models. STAC3 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, STAC3 is differentially expressed in 16, with the highest sampling consensus in KIRC. Additionally, STAC3 RNA expression shows 16,225 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRC, and TGCT as cancer lineages where STAC3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for STAC3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes STAC3 survival associations across molecular data types. STAC3 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (3) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible STAC3 RNA expression–survival associations across cancer types. High STAC3 expression shows unfavorable associations in KIRC, ACC and LGG, but favorable associations in SKCM, BLCA and CESC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for STAC3 RNA expression.
This table summarizes STAC3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 1. The strongest signals are observed in KIRC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for STAC3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. STAC3 shows lower tumor expression in LUAD and LUSC and higher tumor expression in KIRC, KIRP, STAD and BLCA. The KIRC box plot shows higher STAC3 RNA expression in tumor versus normal tissue (log2 FC = +1.882, t-test p < 0.001).
This table shows molecular features associated with STAC3 in patient tissues and cancer cell lines. In patient samples, STAC3 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, STAC3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and BONE.
